Related Experiment Videos
Pituitary tumour therapy: using the biology
Julian R E Davis1, Peter J Trainer
1Department of Endocrinology, Manchester Royal Infirmary &Christie Hospital, Manchester, UK.
Journal of Neuroendocrinology
|January 11, 2003
Summary
Pituitary tumors cause health problems due to pressure and hormone imbalances. Advances in endocrine therapy, including dopamine agonists and somatostatin analogues, are improving treatment outcomes for these tumors.
Area of Science:
- Endocrinology
- Neuro-oncology
- Pharmacology
Background:
- Pituitary tumors, though benign, present significant clinical challenges.
- These challenges arise from mass effects on adjacent brain structures.
- Hormonal imbalances, including excess or deficiency syndromes, are common.
Purpose of the Study:
- To review the current landscape of pituitary tumor treatment.
- To highlight recent advancements in endocrine therapies.
- To discuss the future potential of biologically-driven treatments.
Main Methods:
- Review of current endocrine therapies for pituitary tumors.
- Discussion of novel therapeutic agents, including growth hormone receptor antagonists.
- Exploration of emerging treatment strategies based on tumor biology.
Main Results:
- Endocrine therapy has shown increasing success in managing pituitary tumors.
- Dopamine agonists and somatostatin analogues are established treatments.
- Growth hormone receptor antagonists represent a recent therapeutic development.
Conclusions:
- Significant progress has been made in the endocrine treatment of pituitary tumors.
- Further advancements are anticipated through a deeper understanding of tumor biology.
- Improved treatment strategies are expected to enhance patient outcomes.